Download PDF

1. Company Snapshot

1.a. Company Description

Equasens Société anonyme provides various IT solutions for the healthcare sector in Europe.It offers LGPI global services and OffiCentral solutions for managing pharmacies and their networks; OffiMSS, OffiSecure, OffiProtect, OffiPass, OffiSeen, OffiCash, Offizzy, and OffiLocker solutions for pharmacists' business processes; and solutions for energizing the customer relationship with pharmacists comprising OffiTag, OffiTouch, OffiMédia, OffiConnect, automation systems, and customer loyalty programs.The company also provides My Pilot, an analytics and management tool; OffiLearning, an e-learning tool; and solutions for patient support and advice, such as compliance monitoring software, Multimeds, Automeds, and OffiTéléconsult, as well as pharmaceutical record and shared medical record services.


In addition, it offers a ULTIMATE, a system combining optimized pharmacy management and improved patient support; FARMACLICK, a protocol for communications between pharmacies and wholesalers-distributors; DIFARM, a solution for wholesalers-distributors; PHARE, a retail management tool; SOPHIA, a pharmacy management application; OffiMédia POS display; eNephro to enhance the care of chronic renal failure patients; and TPE Pilot, a web-based application that simplifies the management and sharing of patient education programs.Further, the company provides NOVIACARE; CARELIB Domicile; CARELIB EHPAD; KAPELSE solutions; TITAN solutions; ANTHADINE software and MOBISOINS mobile tool; MICROSOINS, an in-home nursing care solution; and LOGICLIC.Additionally, it offers AXIGATE solutions to manage the entire patient care pathway; CHORUS platform; medical telesecretarial services for healthcare professionals; and equipment lease financing solutions.


The company was incorporated in 1996 and is based in Villers-les-Nancy, France.Equasens Société anonyme is a subsidiary of Marque Verte Sante.

Show Full description

1.b. Last Insights on EQS

Equasens Société anonyme's recent performance was negatively impacted by a decline in like-for-like revenue, down 0.4% year-over-year in 2024. The company's Q4 revenue growth was also weak, increasing 2.6% on a reported basis and 1.4% on a like-for-like basis. Additionally, the acquisition of Calimed, a SaaS software expert, may not have yet contributed to the company's revenue growth, as the deal was announced in December 2024 and the impact may take time to materialize.

1.c. Company Highlights

2. Transcript Summary

Unfortunately this company is not part of our coverage yet. But as part of your subscription plan you can request it by clicking just below and we'll process.

3. NewsRoom

Card image cap

Equasens: Q3 2025 revenue

Nov -05

Card image cap

European Dividend Stocks To Consider In October 2025

Oct -21

Card image cap

Equasens: 2025 half-year results

Sep -26

Card image cap

Equasens: H1 revenue at 30 June 2025: €116.0m

Jul -31

Card image cap

Equasens: Appointment at the head of the Pharmagest Division

Jul -03

Card image cap

Equasens: General meeting - Results of the votes

Jul -01

Card image cap

Equasens: acquisition of DIS and RESURGENCES BUSINESSES

Jun -30

Card image cap

Equasens: availability of AGM preparatory materials

Jun -06

4. Business Breakdown

4.a. Revenues by Country

4.b. Revenues by Segment

5. Expected revenues mid-term growth (5.62%)

6. Segments

Pharmagest

Expected Growth: 6%

Pharmagest's 6% growth is driven by increasing demand for healthcare services, expansion into new markets, and strategic acquisitions. The company's diversified business model, including pharmacy management software and healthcare services, contributes to its growth. Additionally, investments in digital transformation and innovation enable Pharmagest to stay competitive and capitalize on emerging trends in the healthcare industry.

Axigate Link

Expected Growth: 5%

Axigate Link's 5% growth is driven by increasing demand for digital transformation, expansion into new markets, and strategic partnerships. The company's innovative solutions in data analytics and artificial intelligence also contribute to its growth. Additionally, the growing need for cybersecurity and compliance in the financial sector further fuels Axigate Link's expansion.

Others

Expected Growth: 4%

Equasens Société anonyme's 4% growth is driven by increasing demand for digital payment solutions, expansion into new markets, and strategic partnerships. Additionally, the company's focus on innovation, cost optimization, and operational efficiency have contributed to its growth. Furthermore, the growing need for secure and reliable payment processing has also boosted the company's revenue.

7. Detailed Products

Equasens Analytics

A data analytics platform that provides insights and trends to help businesses make informed decisions

Equasens Risk Management

A risk management solution that helps businesses identify and mitigate potential risks

Equasens Compliance

A compliance solution that helps businesses meet regulatory requirements and avoid penalties

Equasens Performance Management

A performance management solution that helps businesses set and achieve goals

Equasens Governance

A governance solution that helps businesses manage and optimize their operations

8. Equasens Société anonyme's Porter Forces

Forces Ranking

Threat Of Substitutes

The threat of substitutes for Equasens Société anonyme is moderate, as there are some alternatives available in the market, but they are not very attractive to customers.

Bargaining Power Of Customers

The bargaining power of customers for Equasens Société anonyme is low, as customers have limited options and the company has a strong brand presence.

Bargaining Power Of Suppliers

The bargaining power of suppliers for Equasens Société anonyme is moderate, as the company has some negotiating power, but suppliers also have some bargaining power.

Threat Of New Entrants

The threat of new entrants for Equasens Société anonyme is high, as the market is attractive and there are low barriers to entry.

Intensity Of Rivalry

The intensity of rivalry for Equasens Société anonyme is high, as the market is highly competitive and there are many players competing for market share.

9. SWOT Analysis

10. Capital Structure

10.a. Balance Sheet

10.b. Weighted Average Cost of capital

Value
Debt Weight 22.00%
Debt Cost 3.95%
Equity Weight 78.00%
Equity Cost 8.45%
WACC 7.46%
Leverage 28.21%

11. Quality Control: Equasens Société anonyme passed 8 out of 9 key points

12.a Historical Valuation

12.b Price/Earnings Ratio

12.c Margin Valuation

12.d Peers Valuation

Peers Group Analysis

Stock-Card
Nexus

A-Score: 5.6/10

Value: 2.0

Growth: 7.2

Quality: 7.9

Yield: 0.0

Momentum: 9.0

Volatility: 7.7

1-Year Total Return ->

Stock-Card
RaySearch Laboratories

A-Score: 4.9/10

Value: 0.5

Growth: 8.4

Quality: 7.6

Yield: 1.2

Momentum: 9.0

Volatility: 2.7

1-Year Total Return ->

Stock-Card
CompuGroup Medical

A-Score: 4.7/10

Value: 4.6

Growth: 4.2

Quality: 4.1

Yield: 0.6

Momentum: 9.5

Volatility: 5.0

1-Year Total Return ->

Stock-Card
Equasens

A-Score: 4.2/10

Value: 4.6

Growth: 4.9

Quality: 7.2

Yield: 4.4

Momentum: 1.0

Volatility: 3.0

1-Year Total Return ->

Stock-Card
Kneat

A-Score: 4.0/10

Value: 2.0

Growth: 7.8

Quality: 3.8

Yield: 0.0

Momentum: 7.5

Volatility: 3.0

1-Year Total Return ->

Stock-Card
Cegedim

A-Score: 4.0/10

Value: 10.0

Growth: 3.7

Quality: 2.3

Yield: 0.0

Momentum: 2.0

Volatility: 6.0

1-Year Total Return ->

Peers Metrics

12.e Scoring Insights

12.f DCF BETA

Parameters

Short Term Growth

Short term Time

Long-Term Growth

WACC

Target Price

43.2$

Current Price

43.2$

Potential

-0.00%

Expected Cash-Flows